ARIAD Pharmaceuticals, Inc.

Timothy P. Clackson, Ph.D. has been named president of R&D, ARIAD Pharmaceuticals, Inc. Dr. Clackson also retains his position as chief scientific officer.

In this new role, Dr. Clackson will be responsible for establishing an integrated R&D organization, including all components of R&D from early discovery through advanced clinical development. He also will continue to oversee manufacturing operations and program and alliance management.

“Tim has contributed immensely to ARIAD’s success over the years and has led our scientific programs with great vision, thoughtfulness and excellence,” said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. “In establishing an integrated research and development organization, we will streamline R&D decision-making and provide for focused coordination among functional groups.”

Dr. Clackson has nearly 20 years of experience in the biopharmaceutical industry. He served as ARIAD’s senior vice president and chief scientific officer since September 2003 and previously held a number of scientific positions, from research scientist through to management during the past 15 years. Dr. Clackson led the multi-disciplinary research group that identified all of ARIAD’s product candidates. He will continue to report to Dr. Berger.

Additionally, Frank G. Haluska, M.D., Ph.D. has been named vice president, Clinical R&D and chief medical officer, reporting to Dr. Clackson. Edward M. Fitzgerald has been promoted to executive vice president and chief financial officer, reporting to Dr. Berger. He will be responsible for oversight of the company’s commercial operations. Pierre F. Dodion, M.D. will move to the newly created position of senior vice president, Corporate Development, reporting to Dr. Berger. He will be responsible for leading business development and corporate strategy for ARIAD.